Key result
Enoxaparin review outlines pharmacological actions and clinical use for VTE prevention in nonsurgical patients.
Why the study?
Enoxaparin has been evaluated in recent studies for VTE and ACS, with its use extending to other settings requiring antithrombotic prevention.
Does enoxaparin prevent venous thromboembolism in nonsurgical patients?
Does enoxaparin prevent venous thromboembolism in nonsurgical patients?
This review summarizes the clinical evidence for using enoxaparin to prevent venous thromboembolism in nonsurgical patients.
Supports enoxaparin for VTE prophylaxis in nonsurgical patients; extends prior syntheses but leaves open need for updated RCTs.
Low-molecular-weight heparins are a class of drugs derived from the enzymatic depolymerization of unfractionated heparin that includes enoxaparin. Several studies have been performed on enoxaparin in recent years, in particular for the prevention and treatment of venous thromboembolism and for the treatment of acute coronary syndrome. Furthermore, the use of enoxaparin has been extended to other clinical situations that require antithrombotic pharmacological prevention, such as hemodialysis and recurrent abortion. In this review, we report the main clinical experiences of using enoxaparin in the prevention of VTE in nonsurgical patients.
No takes yet. Share an insight, caveat, or question.
Imbalzano et al. (2024) conducted a review in Venous thromboembolism in nonsurgical patients. Enoxaparin was evaluated. Enoxaparin is reviewed for its pharmacological actions and clinical use in the prevention of venous thromboembolism in nonsurgical patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: